Alto Neuroscience, Inc.

NYSE:ANRO

Biotechnology

Healthcare
$25.91 +1.84%

+$0.40 today

Market cap
$1.04B
Beta
1.25
P/E (TTM)
-9.8
EPS (TTM)
-$2.26
52W Low $2.15High $28.44

Volume 0.99M

Average 0.34M

ANRO Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Alto Neuroscience, Inc.NYSE: ANRO

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents rises 64.1% from a year ago

Cash & equivalents stood at $263.76M at the end of Q1 FY2026, up 64.1% from a year earlier and up 49.5% from the prior quarter. Over 3 fiscal years it compounded at +54.0% a year.

Context

  • Cash & equivalents amounted to 95.5% of total assets at the end of Q1 FY2026, up 2.0 pp from a year earlier.
  • Cash & equivalents increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +64.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$263.76M+49.5% QoQ
Last fiscal yearDec 2025
$176.48M+4.9% YoY
Year agoMar 2025
$160.75M+64.1% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+64.1%——
1 year+4.9%——
3-year CAGR+54.0%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
176.48M USD
Year-over-year change
+4.9%
4-year CAGR
+61.9%

Cash & Equivalents vs competitors

How ANRO compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +64.1% is the 4th highest of 11, against a peer median of +2.9%.
  • Cash & equivalents amounts to 95.5% of total assets for ANRO, versus a peer median of 17.1%.
ANRO Competitors
Cash & Equivalents for ANRO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ANROAlto Neuroscience, Inc.Mar 2026$263.76M USD+64.1%+54.0%95.5%
DBVTDBV Technologies S.A.Mar 2026$229.2M USD+1668.2%-2.5%86.0%
LRMRLarimar Therapeutics, Inc.Mar 2026$177.91M USD+742.2%+47.1%85.3%
AMRNAmarin Corporation plcMar 2026$131.06M USD+9.7%-14.7%20.3%
ALDXAldeyra Therapeutics, Inc.Mar 2026$65M USD+29.1%-21.4%97.8%
KRROKorro Bio, Inc.Mar 2026$61.7M USD-3.8%-16.1%33.6%
CLLSCellectis S.A.Mar 2026$35M USD-72.6%-10.9%12.1%
CTNMContineum Therapeutics, Inc. Class A Common StockMar 2026$20.16M USD-10.3%+138.6%7.7%
ACIUAC Immune S.A.Mar 2026CHF 19.17M CHF-4.0%-5.3%13.9%
DRTSAlpha Tau Medical Ltd.Mar 2026$8.44M USD+68.2%+39.9%7.8%
SLNSilence Therapeutics plcMar 2026$5.66M USD-91.3%-41.0%4.9%
Peer median (excluding ANRO) —+2.9%-8.1%17.1%

Competitors are the stored peer set for ANRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents25.71M48.34M82.55M168.23M176.48M
Short-term Investments00000
Net Receivables1.74M546K8K00
Inventory00000
Other Current Assets002.31M30K1.23M
Total Current Assets27.68M49.22M85.39M169.34M177.72M
Property, Plant & Equipment (Net)1.06M1.58M1.11M7.7M6.13M
Goodwill00000
Intangible Assets00000
Long-term Investments000500K500K
Tax Assets00000
Other Non-current Assets50K55K131K4K338K
Total Non-current Assets1.11M1.63M1.24M8.21M6.97M
Total Assets28.79M50.85M86.63M177.54M184.69M
Account Payables600K1.61M1.07M1.58M1.88M
Short-term Debt0283K00585K
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities1.19M3.54M008.86M
Total Current Liabilities1.81M5.56M5.61M10.01M11.33M
Long-term Debt38.16M81.7M9.86M11.56M3.82M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities1.3M1.88M142.83M018.4M
Total Non-current Liabilities39.46M83.7M152.69M16.07M22.22M
Total Liabilities41.27M89.26M158.3M26.08M33.55M
Common Stock1K1K03K3K
Retained Earnings(12.95M)(40.66M)(76.97M)(138.4M)(201.63M)
Accumulated OCI(22K)(46K)(79K)(101K)22K
Other Stockholders Equity00000
Minority Interest00000
Total Equity(12.48M)(38.41M)(71.67M)151.46M151.14M
Total Debt38.16M82.11M9.99M16.94M4.41M
Net Debt12.46M33.76M(72.56M)(151.29M)(172.08M)

Alto Neuroscience, Inc.

NYSE:ANRO

Intrinsic Alpha fair value

Locked

Current Price

$25.91

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.